PMV Pharmaceuticals, Inc.
PMVPPMV Pharmaceuticals, Inc. in brief
PMV Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in California, USA. Its market value was $113 M on 9 October 2026, which makes it the 18,312th largest listed company in the world and the 3,465th largest in the USA on this site. It employs about 35 people and David Henry Mack is its chief executive. Its shares trade under the symbol PMVP (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals is a management team of Biopharmaceutical experts with extensive experience in oncology drug discovery and development company. The company annual net income is 4.9 million USD. The headquarters is in USA.
PMV Pharmaceuticals, Inc. timeline
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 25 September 2020; shares registered for exchange trading on 21 September 2020.
Events of PMV Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,431 (Jan 2021) · #2,697 (Jan 2022) · #2,855 (Dec 2022) · #3,175 (Jul 2023) · #3,443 (Jan 2024) · #1,972 (Mar 2026) · #3,626 (Aug 2026) · #3,437 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.1×
- Free cash flow yield
- -65.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -74.2%
- Liabilities / assets
- 10.2%
- Profit per employee
- $-2.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-86M | $-78M | — |
| Dec 2024 | — | — | $-85M | $-59M | — |
| Dec 2023 | — | — | $-80M | $-69M | — |
| Dec 2022 | — | — | $-77M | $-73M | — |
| Dec 2021 | — | — | $-58M | $-58M | — |
| Dec 2020 | — | — | $-35M | $-34M | — |
| Dec 2019 | — | — | $-27M | $-25M | — |
| Dec 2018 | — | — | $-19M | $-18M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-74M | $0M | $-74M | $-1.48 | — |
| Dec 2024 | $-51M | $1M | $-52M | $-1.14 | — |
| Dec 2023 | $-56M | $1M | $-57M | $-1.44 | — |
| Dec 2022 | $-64M | $8M | $-72M | $-1.61 | — |
| Dec 2021 | $-47M | $1M | $-48M | $-1.28 | — |
| Dec 2020 | $-33M | $0M | $-33M | $-2.40 | — |
| Dec 2019 | $-22M | $0M | $-22M | $-8.35 | — |
| Dec 2018 | $-15M | $0M | $-16M | $-5.82 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-34M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 5, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Sep 2, 20268-KCurrent reportMaterial agreement · Other events
- Aug 31, 20268-KCurrent reportOther events
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportResults of operations
- Jun 5, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 22, 2026DEF 14AProxy statement
- Mar 6, 20268-KCurrent reportResults of operations
Official filings of PMV Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-86 M
- Net income
- $-78 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $117 M
- Total liabilities
- $12 M
- Total equity
- $105 M
As of December-2025
Top 65 institutional investors in PMV Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BML Capital Management, LLC | 7,330,000 | +2,000,000 (+37.52%) | 9.70% | $12 M | Nov 6, 2026 |
| 2 | Tang Capital Management LLC | 7,285,085 | +3,040,000 (+71.61%) | 9.64% | $12 M | Nov 16, 2026 |
| 3 | Samsara Biocapital, LLC | 7,240,000 | New | 9.59% | $12 M | Nov 16, 2026 |
| 4 | Sio Capital Management, LLC | 3,634,137 | +1,000,000 (+37.96%) | 4.81% | $6 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 3,083,667 | +1,071,647 (+53.26%) | 4.08% | $5 M | Nov 13, 2026 |
| 6 | ADAR1 Capital Management, LLC | 2,700,349 | +2,499,341 (+1243.40%) | 3.58% | $5 M | Nov 16, 2026 |
| 7 | Euclidean Capital LLC | 2,627,643 | 0 (0.00%) | 3.48% | $4 M | Nov 16, 2026 |
| 8 | Two Sigma Investments, LP | 2,429,330 | +475,194 (+24.32%) | 3.22% | $4 M | Nov 16, 2026 |
| 9 | Adage Capital Partners GP, L.L.C. | 2,360,000 | 0 (0.00%) | 3.12% | $4 M | Nov 16, 2026 |
| 10 | Acadian Asset Management LLC | 2,285,479 | +69,585 (+3.14%) | 3.03% | $4 M | Nov 9, 2026 |
| 11 | Boxer Capital Management, LLC | 2,050,000 | New | 2.71% | $3 M | Nov 16, 2026 |
| 12 | Eversept Partners, LP | 1,964,624 | +73,720 (+3.90%) | 2.60% | $3 M | Nov 16, 2026 |
| 13 | Affinity Asset Advisors, LLC | 1,750,000 | New | 2.32% | $3 M | Nov 13, 2026 |
| 14 | ArrowMark Colorado Holdings LLC | 1,694,798 | -264,781 (-13.51%) | 2.24% | $3 M | Nov 16, 2026 |
| 15 | Millennium Management LLC | 1,461,926 | New | 1.94% | $2 M | Nov 16, 2026 |
| 16 | BlackRock, Inc. | 916,518 | -3,300 (-0.36%) | 1.21% | $2 M | Nov 13, 2026 |
| 17 | BIT Capital GmbH | 714,407 | +306,852 (+75.29%) | 0.95% | $1 M | Nov 13, 2026 |
| 18 | Geode Capital Management, LLC | 500,327 | +27,169 (+5.74%) | 0.66% | $1 M | Nov 6, 2026 |
| 19 | Aldebaran Capital, LLC | 489,540 | +22,108 (+4.73%) | 0.65% | $1 M | Nov 13, 2026 |
| 20 | Walleye Capital LLC | 487,141 | +151,447 (+45.11%) | 0.64% | $1 M | Nov 13, 2026 |
| 21 | Bridgeway Capital Management, LLC | 427,528 | -1,325 (-0.31%) | 0.57% | $1 M | Nov 16, 2026 |
| 22 | Assenagon Asset Management S.A. | 328,744 | -331,262 (-50.19%) | 0.44% | $1 M | Oct 15, 2026 |
| 23 | Vanguard Fiduciary Trust Co | 301,866 | +47,091 (+18.48%) | 0.40% | $1 M | Nov 13, 2026 |
| 24 | Citadel Advisors LLC | 268,338 | +221,030 (+467.21%) | 0.36% | $0 M | Nov 16, 2026 |
| 25 | Bank Of America Corp /de/ | 265,898 | +25,788 (+10.74%) | 0.35% | $0 M | Nov 16, 2026 |
Show all 65: investors 26 to 65
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Marshall Wace, LLP | 220,760 | -100,850 (-31.36%) | 0.29% | $0 M | Nov 13, 2026 |
| 27 | State Street Corp | 183,178 | 0 (0.00%) | 0.24% | $0 M | Nov 12, 2026 |
| 28 | RBF Capital, LLC | 162,200 | 0 (0.00%) | 0.21% | $0 M | Nov 13, 2026 |
| 29 | Goldman Sachs Group Inc | 156,869 | +19,875 (+14.51%) | 0.21% | $0 M | Nov 16, 2026 |
| 30 | MAI Capital Management | 133,122 | 0 (0.00%) | 0.18% | $0 M | Nov 12, 2026 |
| 31 | Susquehanna International Group, LLP | 130,673 | +93,142 (+248.17%) | 0.17% | $0 M | Nov 16, 2026 |
| 32 | Connor, Clark & Lunn Investment Management Ltd. | 110,086 | +77,626 (+239.14%) | 0.15% | $0 M | Nov 10, 2026 |
| 33 | HRT Financial LP | 103,270 | +52,760 (+104.45%) | 0.14% | $0 M | Nov 13, 2026 |
| 34 | Rangeley Capital, LLC | 99,240 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 35 | Northern Trust Corp | 93,047 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 36 | Ikarian Capital, LLC | 89,136 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 37 | Empowered Funds, LLC | 75,575 | New | 0.10% | $0 M | Nov 13, 2026 |
| 38 | Accurate Wealth Management, LLC | 50,000 | 0 (0.00%) | 0.07% | $0 M | Oct 20, 2026 |
| 39 | Jacobs Levy Equity Management, Inc | 35,817 | -34,687 (-49.20%) | 0.05% | $0 M | Nov 16, 2026 |
| 40 | HSBC Holdings PLC | 30,891 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 41 | Barclays PLC | 27,536 | -225 (-0.81%) | 0.04% | $0 M | Nov 6, 2026 |
| 42 | Gsa Capital Partners LLP | 27,382 | New | 0.04% | $0 M | Nov 16, 2026 |
| 43 | Boothbay Fund Management, LLC | 27,126 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 44 | Quadrature Capital Ltd | 23,756 | -38,314 (-61.73%) | 0.03% | $0 M | Nov 13, 2026 |
| 45 | Vanguard Global Advisers, LLC | 21,559 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 46 | Point72 Asset Management, L.P. | 18,819 | New | 0.02% | $0 M | Nov 16, 2026 |
| 47 | Pathstone Holdings, LLC | 17,487 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 48 | Corient Private Wealth LP | 15,000 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 49 | Jane Street Group, LLC | 14,245 | -25,962 (-64.57%) | 0.02% | $0 M | Nov 12, 2026 |
| 50 | Morgan Stanley | 13,719 | -27,965 (-67.09%) | 0.02% | $0 M | Nov 13, 2026 |
| 51 | Sand Hill Global Advisors, LLC | 12,539 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 52 | Independent Advisor Alliance | 12,500 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 53 | Claret Asset Management Corp | 10,703 | New | 0.01% | $0 M | Nov 16, 2026 |
| 54 | Deerfield Management Company, L.P. | 8,790 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 55 | Silver Grove Financial Group, Inc. | 5,082 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 56 | PNC Financial Services Group, Inc. | 2,205 | -65,733 (-96.75%) | 0.00% | $0 M | Nov 6, 2026 |
| 57 | Russell Investments Group, Ltd. | 2,001 | New | 0.00% | $0 M | Nov 6, 2026 |
| 58 | Jones Financial Companies Lllp | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 59 | Tower Research Capital LLC (TRC) | 1,000 | -64 (-6.02%) | 0.00% | $0 M | Nov 16, 2026 |
| 60 | Jpmorgan Chase & Co | 614 | +400 (+186.92%) | 0.00% | $0 M | Nov 12, 2026 |
| 61 | BNP Paribas Financial Markets | 518 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 62 | Caitong International Asset Management Co., Ltd | 375 | +357 (+1983.33%) | 0.00% | $0 M | Oct 29, 2026 |
| 63 | UBS Group AG | 361 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 64 | Group One Trading LLC | 155 | +65 (+72.22%) | 0.00% | $0 M | Nov 10, 2026 |
| 65 | Royal Bank Of Canada | 77 | +1 (+1.32%) | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding PMV Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.49 M | $2 M | 2.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC | 1.06 M | $1 M | 1.4% | 0.52% | −2.1% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 452,363 | $1 M | 0.60% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 232,874 | $0 M | 0.31% | <0.01% | +5.0% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 160,526 | $0 M | 0.21% | 0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 76,900 | $0 M | 0.10% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 74,050 | $0 M | 0.10% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 71,190 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 59,924 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 45,045 | $0 M | 0.06% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 41,912 | $0 M | 0.06% | <0.01% | −15% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 43,138 | $0 M | 0.06% | <0.01% | +258% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 27,547 | $0 M | 0.04% | <0.01% | −18% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 14,496 | $0 M | 0.02% | <0.01% | −68% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 13,167 | $0 M | 0.02% | <0.01% | −18% | Jun 30, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 13,237 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 11,700 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,722 | $0 M | 0.01% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 7,891 | $0 M | 0.01% | <0.01% | −67% | Jun 30, 2026 |
| 🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust | 4,716 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation | 356 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 295 | $0 M | <0.01% | <0.01% | +6.1% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 22 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at PMV Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David Henry MackPresident and CEO, Director | Option exercise | +220,643 | $1.370 | $302 K | 451,109 | Form 4 |
| filed | OrbiMed Capital GP V LLC10% owner | Sellindirect | -1.00 M | $1.520 | $1.5 M | 4.98 M | Form 4 |
| filed | Orbimed Advisors LLC10% owner | Sellindirect | -500,000 | $1.800 | $900 K | 5.98 M | Form 4 |
| filed | Michael CarulliChief Financial Officer | Sell | -28,249 | $1.060 | $30 K | 60,146 | Form 4 |
| filed | Deepika JalotaChief Development Officer | Sell | -33,065 | $1.060 | $35 K | 89,959 | Form 4 |
| filed | David Henry MackPresident and CEO, Director | Sell | -58,411 | $1.060 | $62 K | 536,133 | Form 4 |
| filed | Robert TicktinGeneral Counsel & COO | Sell | -23,151 | $1.060 | $25 K | 98,695 | Form 4 |
| filed | David Henry MackPresident and CEO, Director | Option exercise | +17,709 | $0.530 | $9 K | 551,919 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: PMV Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 5.265-for-1 split
Fails to deliver
- : 623 shares at $1.49
- : 4,474 shares at $1.31
- : 1,839 shares at $1.26
- : 1 shares at $1.15
- : 2,933 shares at $1.44
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
PMV Pharmaceuticals, Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 9, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.1×Price to book 1.1× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-65.4%Free cash flow is -65.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.48 vs -1.14Diluted EPS -1.48 in fiscal 2025 against -1.14 the year before (report's currency).
- ✗Net income higher than five years earlier-$78 M-$78 M in fiscal 2025 against -$34 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$78 MNet income -$78 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-55.4%-55.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities10.1×Current ratio 10.09 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.9%Diluted shares up 1.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
PMV Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Research and development | 70+19.4%— | 59+4.7%— | 56+7.5%— | 52+42.5%— | 36+52.5%— | 24+15.3%— | 21+49.9%— | 14—— | |
| General and administrative | 16−39.3%— | 27+11.0%— | 24−3.2%— | 25+14.9%— | 22+98.0%— | 11+87.3%— | 5.9+16.7%— | 5.0—— | |
| Operating expenses | 86+0.9%— | 85+6.6%— | 80+4.0%— | 77+32.2%— | 58+66.8%— | 35+31.2%— | 27+41.0%— | 19—— | |
| Operating income | −86—— | −85—— | −80—— | −77—— | −58—— | −35—— | −27—— | −19—— | |
| Net interest income | 6.3−40.5%— | 11−4.6%— | 11+208%— | 3.6+708%— | 0.4−31.0%— | 0.7−50.0%— | 1.3−3.0%— | 1.3—— | |
| Other non-operating income (expense) | 6.3−40.9%— | 11−4.8%— | 11+201%— | 3.7+690%— | 0.5−7.5%— | 0.5−60.7%— | 1.3−4.7%— | 1.4—— | |
| Income before tax | −80—— | −75—— | −69—— | −73—— | −58—— | −34—— | −25—— | −18—— | |
| Income tax | −2.2—— | −16−805100%— | 0.0—— | −0.0−139%— | 0.0+283%— | 0.0−25.0%— | 0.0+167%— | 0.0—— | |
| Net income including minority interests | −78—— | −59—— | −69—— | −73—— | −58—— | −34—— | −25—— | −18—— | |
| Net income attributable to shareholders | −78—— | −59—— | −69—— | −73—— | −58—— | −34—— | −25—— | −18—— | |
| Earnings per share, basic | -1.48—— | -1.14—— | -1.44—— | -1.61—— | -1.28—— | -2.40—— | -8.35—— | -5.82—— | |
| Earnings per share, diluted | -1.48—— | -1.14—— | -1.44—— | -1.61—— | -1.28—— | -2.40—— | -8.35—— | -5.82—— | |
| Shares, weighted average (basic) | 53+1.9%— | 52+7.4%— | 48+5.3%— | 46+1.0%— | 45+214%— | 14—— | — | — | |
| Shares, weighted average (diluted) | 53+1.9%— | 52+7.4%— | 48+5.3%— | 46+1.0%— | 45+214%— | 14+373%— | 3.0+0.8%— | 3.0—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 38−7.1%32.6% | 41+8.4%21.4% | 38−65.2%15.0% | 108−37.2%40.1% | 172−52.3%52.0% | 361+393%98.9% | 73—71.1% | — | |
| Short-term investments | 75−41.7%64.3% | 129−22.2%67.2% | 165+24.6%65.6% | 133+6.5%49.1% | 125—37.6% | — | 28—27.4% | — | |
| Other current assets | 2.3−63.2%2.0% | 6.2+75.8%3.2% | 3.5−31.2%1.4% | 5.1+55.4%1.9% | 3.3−1.1%1.0% | 3.3+450%0.9% | 0.6—0.6% | — | |
| Current assets | 115−34.4%98.9% | 176−15.3%91.8% | 207−16.0%82.3% | 247−18.0%91.4% | 301−17.4%90.9% | 365+257%99.8% | 102—99.1% | — | |
| Property, plant and equipment | 0.2−42.1%0.2% | 0.4−96.2%0.2% | 11−2.6%4.2% | 11+255%4.1% | 3.1+443%0.9% | 0.6−23.0%0.2% | 0.7—0.7% | — | |
| Right-of-use (leased) assets | 0.8−29.9%0.7% | 1.1−86.4%0.6% | 8.4−12.1%3.3% | 9.5−5.2%3.5% | 10—3.0% | — | — | — | |
| Total assets | 117−39.1%100% | 191−24.1%100% | 252−6.7%100% | 270−18.5%100% | 332−9.3%100% | 366+255%100% | 103—100% | — | |
| Accounts payable | 3.2−52.0%2.7% | 6.6+103%3.4% | 3.2+8.0%1.3% | 3.0−6.1%1.1% | 3.2+98.4%1.0% | 1.6−43.4%0.4% | 2.8—2.8% | — | |
| Current liabilities | 11−20.6%9.8% | 14+2.4%7.5% | 14+29.5%5.6% | 11−11.4%4.0% | 12+90.6%3.7% | 6.4+41.7%1.8% | 4.5—4.4% | — | |
| Lease liabilities (non-current) | 0.4−48.1%0.4% | 0.8−93.3%0.4% | 12−7.5%4.9% | 13+24.6%5.0% | 11—3.3% | — | — | — | |
| Total liabilities | 12−22.1%10.2% | 15−42.5%8.0% | 26+9.0%10.5% | 24+5.5%9.0% | 23+259%6.9% | 6.4+40.1%1.8% | 4.6—4.4% | — | |
| Retained earnings | −446—−383% | −369—−193% | −310—−123% | −241—−89.2% | −168—−50.6% | −110—−30.1% | −75—−73.2% | — | |
| Shareholders' equity | 105−40.5%89.8% | 176−22.0%92.0% | 226−8.3%89.5% | 246−20.3%91.0% | 309−14.1%93.1% | 359—98.2% | −70—−68.4% | −46—— | |
| Total liabilities and equity | 117−39.1%100% | 191−24.1%100% | 252−6.7%100% | 270−18.5%100% | 332−9.3%100% | 366+255%100% | 103—100% | — | |
| Shares outstanding | 53+2.7%— | 52+1.0%— | 51+12.4%— | 46+0.7%— | 45+1.5%— | 45+1370%— | 3.0—— | — | |
| Cash-flow statement | |||||||||
| Share-based compensation | 5.9−33.2%— | 8.9−28.3%— | 12+21.4%— | 10+90.9%— | 5.3+176%— | 1.9+113%— | 0.9−15.8%— | 1.1—— | |
| Cash from operating activities | −74—— | −51—— | −56—— | −64—— | −47—— | −33—— | −22—— | −15—— | |
| Capital expenditure | −0.0—— | −0.7—— | −1.0—— | −8.0—— | −1.3—— | −0.1—— | −0.1—— | −0.5—— | |
| Cash from investing activities | 70+31.5%— | 53—— | −51—— | −1.4—— | −144−614%— | 28+764%— | 3.2−85.1%— | 22—— | |
| Shares issued | — | — | 35—— | — | — | 223—— | — | — | |
| Cash from financing activities | 0.5+61.3%— | 0.3−99.1%— | 36+3614%— | 1.0−52.6%— | 2.0−99.3%— | 293+374%— | 62—— | — | |
| Change in cash | −2.9−223%— | 2.3—— | −71—— | −64—— | −188−165%— | 288+571%— | 43+560%— | 6.5—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 62−8.7%— | 16−11.8%— | 15−20.2%— | 15−12.1%— | 16*+15.0%— | 18+7.5%— | 18+25.8%— | 17+32.3%— | 14*+2.9%— | 17—— | 15—— | 13—— | 13*—— | |
| General and administrative | 15−37.0%— | 4.0−7.2%— | 4.2−6.1%— | 3.7−10.5%— | 3.4*−70.0%— | 4.3−12.7%— | 4.5−19.2%— | 4.1−18.1%— | 11*+107%— | 4.9—— | 5.5—— | 5.0—— | 5.5*—— | |
| Operating expenses | 77−16.2%— | 20−10.9%— | 19−17.5%— | 19−11.8%— | 19*−23.5%— | 23+2.9%— | 23+13.4%— | 22+18.3%— | 25*+33.1%— | 22—— | 20—— | 18—— | 19*—— | |
| Operating income | −77—— | −20—— | −19—— | −19—— | −19*—— | −23—— | −23—— | −22—— | −25*—— | −22—— | −20—— | −18—— | −19*—— | |
| Net interest income | 3.8−48.2%— | 0.8−43.9%— | 0.8−53.4%— | 1.0−49.4%— | 1.2*−46.1%— | 1.5−43.4%— | 1.7−39.7%— | 1.9−34.5%— | 2.3*−27.8%— | 2.6—— | 2.8—— | 3.0—— | 3.2*—— | |
| Other non-operating income (expense) | −11−256%— | −14−1083%— | 0.8−52.3%— | 1.0−49.2%— | 1.2*−43.2%— | 1.5−46.7%— | 1.7−39.9%— | 1.9−34.6%— | 2.2*−31.1%— | 2.7—— | 2.8—— | 3.0—— | 3.1*—— | |
| Income before tax | −89—— | −34—— | −18—— | −18—— | −18*—— | −21—— | −21—— | −20—— | −23*—— | −19—— | −17—— | −15—— | −16*—— | |
| Income tax | — | −0.0—— | 0.0−40.0%— | — | 0.0*—— | −0.0−108%— | 0.0—— | −2.2—— | 0*—— | 0.1—— | −16—— | — | −0.0*—— | |
| Net income including minority interests | −89—— | −34*—— | −18*—— | −18—— | −18*—— | −21*—— | −21*—— | −17—— | −23*—— | −19*—— | −1.2*—— | −15—— | −16*—— | |
| Net income attributable to shareholders | −89—— | −34—— | −18—— | −18—— | −18*—— | −21—— | −21—— | −17—— | −23*—— | −19—— | −1.2—— | −15—— | −16*—— | |
| Earnings per share, basic | — | -0.52—— | -0.34—— | -0.34—— | — | -0.40—— | -0.41—— | -0.34—— | — | -0.37—— | -0.02—— | -0.30—— | — | |
| Earnings per share, diluted | — | -0.52—— | -0.34—— | -0.34—— | — | -0.40—— | -0.41—— | -0.34—— | — | -0.37—— | -0.02—— | -0.30—— | — | |
| Shares, weighted average (basic) | 66+25.0%— | 66+25.0%— | 53+2.6%— | 53+2.7%— | — | 53+2.8%— | 52+1.0%— | 52+1.0%— | — | 52—— | 51—— | 51—— | — | |
| Shares, weighted average (diluted) | 66+25.0%— | 66+25.0%— | 53+2.6%— | 53+2.7%— | — | 53+2.8%— | 52+1.0%— | 52+1.0%— | — | 52—— | 51—— | 51—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 20—17.9% | 20−45.0%17.9% | 12−71.7%15.2% | 39−23.8%40.5% | 38−7.1%32.6% | 36−25.6%27.1% | 44−9.1%28.9% | 51+7.7%30.1% | 41+8.4%21.4% | 49—21.8% | 49—20.4% | 48—20.1% | 38—15.0% | |
| Short-term investments | 83—74.1% | 83−11.1%74.1% | 67−31.8%81.6% | 54−50.1%56.4% | 75−41.7%64.3% | 93−30.7%69.4% | 98−40.3%64.2% | 109−27.4%63.9% | 129−22.2%67.2% | 134—60.0% | 164—69.2% | 150—63.4% | 165—65.6% | |
| Other current assets | 2.3—2.1% | 2.3−27.0%2.1% | 2.0−34.9%2.4% | 2.2−28.3%2.3% | 2.3−63.2%2.0% | 3.2−46.3%2.4% | 3.0−39.8%2.0% | 3.1−15.9%1.8% | 6.2+75.8%3.2% | 6.0—2.7% | 5.0—2.1% | 3.7—1.6% | 3.5—1.4% | |
| Current assets | 105—94.2% | 105−20.8%94.2% | 81−44.0%99.2% | 96−41.4%99.2% | 115−34.4%98.9% | 132−30.2%99.0% | 145−33.6%95.1% | 163−19.2%95.8% | 176−15.3%91.8% | 190—84.8% | 219—92.1% | 202—85.5% | 207—82.3% | |
| Property, plant and equipment | 0.1—0.1% | 0.1−48.6%0.1% | 0.2−46.3%0.2% | 0.2−46.0%0.2% | 0.2−42.1%0.2% | 0.3−97.5%0.2% | 0.3−97.3%0.2% | 0.4−96.6%0.2% | 0.4−96.2%0.2% | 10—4.5% | 11—4.4% | 11—4.6% | 11—4.2% | |
| Right-of-use (leased) assets | 0.1—0.1% | 0.1−85.1%0.1% | 0.2−78.6%0.3% | 0.3−73.3%0.3% | 0.8−29.9%0.7% | 0.9−89.4%0.7% | 1.0−87.8%0.6% | 1.1−87.1%0.6% | 1.1−86.4%0.6% | 8.4—3.8% | 8.0—3.4% | 8.2—3.5% | 8.4—3.3% | |
| Total assets | 111—100% | 111−16.8%100% | 82−46.3%100% | 97−43.4%100% | 117−39.1%100% | 134−40.1%100% | 153−35.7%100% | 171−28.0%100% | 191−24.1%100% | 223—100% | 238—100% | 237—100% | 252—100% | |
| Accounts payable | 1.6—1.5% | 1.6−51.8%1.5% | 2.0−22.2%2.5% | 1.6−54.6%1.7% | 3.2−52.0%2.7% | 3.4+64.8%2.5% | 2.6−42.7%1.7% | 3.6+318%2.1% | 6.6+103%3.4% | 2.1—0.9% | 4.5—1.9% | 0.9—0.4% | 3.2—1.3% | |
| Current liabilities | 11—9.6% | 11−13.1%9.6% | 11−9.0%12.9% | 8.6−11.9%8.9% | 11−20.6%9.8% | 12−9.3%9.2% | 12+1.9%7.6% | 9.8−19.1%5.7% | 14+2.4%7.5% | 14—6.1% | 11—4.8% | 12—5.1% | 14—5.6% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.4−48.1%0.4% | 0.5−95.5%0.4% | 0.6−94.6%0.4% | 0.7−93.9%0.4% | 0.8−93.3%0.4% | 12—5.4% | 12—5.0% | 12—5.1% | 12—4.9% | |
| Total liabilities | 54—48.7% | 54+323%48.7% | 11−13.7%12.9% | 8.6−18.2%8.9% | 12−22.1%10.2% | 13−49.8%9.6% | 12−47.3%8.0% | 11−56.6%6.2% | 15−42.5%8.0% | 26—11.4% | 23—9.8% | 24—10.2% | 26—10.5% | |
| Retained earnings | −517—−464% | −517—−464% | −483—−588% | −464—−481% | −446—−383% | −428—−320% | −407—−266% | −386—−226% | −369—−193% | −346—−155% | −326—−137% | −325—−137% | −310—−123% | |
| Shareholders' equity | 57—51.3% | 57−52.8%51.3% | 72−49.1%87.1% | 88−45.1%91.1% | 105−40.5%89.8% | 121−38.9%90.4% | 141−34.4%92.0% | 160−24.7%93.8% | 176−22.0%92.0% | 198—88.6% | 214r214—90.2% | 213—89.8% | 226—89.5% | |
| Total liabilities and equity | 111—100% | 111−16.8%100% | 82−46.3%100% | 97−43.4%100% | 117−39.1%100% | 134−40.1%100% | 153−35.7%100% | 171−28.0%100% | 191−24.1%100% | 223—100% | 238—100% | 237—100% | 252—100% | |
| Shares outstanding | 76—— | 76+42.5%— | 53+0.9%— | 53+2.7%— | 53+2.7%— | 53+2.4%— | 53+2.9%— | 52+1.0%— | 52+1.0%— | 52—— | 52—— | 51—— | 51—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 5.9+1.3%— | 1.6+16.1%— | 1.5−7.5%— | 1.4−7.7%— | 1.4*+7.4%— | 1.4−37.8%— | 1.7−39.7%— | 1.5−42.2%— | 1.3*−57.1%— | 2.2—— | 2.8—— | 2.6—— | 3.0*—— | |
| Cash from operating activities | −70—— | −18*—— | −15*—— | −20—— | −17*—— | −20*—— | −18*—— | −18—— | −17*—— | −17*—— | −1.6*—— | −16—— | −12*—— | |
| Capital expenditure | −0.0—— | 0*—— | 0*—— | 0—— | −0.0*—— | — | −0.0*—— | −0.0—— | −0.1*—— | −0.0*—— | −0.0*—— | −0.6—— | −0.2*—— | |
| Cash from investing activities | 5.8−90.2%— | −21*−276%— | −12*−211%— | 21−27.5%— | 18*+138%— | 12*−29.7%— | 11*+373%— | 29+9.7%— | 7.7*—— | 17*—— | 2.3*—— | 26—— | −2.6*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cash from financing activities | 47+16546%— | 47*—— | 0.1*+38.8%— | 0−100%— | 0.4*+128%— | 0*—— | 0.1*−27.0%— | 0.0—— | 0.2*−40.3%— | 0*—— | 0.1*—— | 0—— | 0.3*—— | |
| Change in cash | −16—— | 7.5*—— | −27*—— | 1.1−89.0%— | 1.6*—— | −7.8*−2843%— | −7.2*−927%— | 10+5.2%— | −8.8*—— | 0.3*—— | 0.9*—— | 9.9—— | −14*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at PMV Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025David H. Mack, Ph.D. | $1.7 M | $958 K | $898 K | $14 |
| 2024David H. Mack, Ph.D. | $4.8 M | $2.2 M | $1.7 M | $7 |
| 2023David H. Mack, Ph.D. | $2.2 M | $514 K | $1.2 M | $13 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at PMV Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Directors and officers 2 · Material agreement 1 · Agreement ended 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Agreement endedResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2017 | $74 M | No. 1 | $50 to $250 million | 9 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at PMV Pharmaceuticals, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $145 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Pharmacokinetic ScientistMedical Scientists, Except Epidemiologists | 1 | $145 K |
Where: Princeton, NJ 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $145 K | 1 |
| FY2024 | 2 | 2 | $68 K | 2 |
| FY2023 | 2 | 2 | $68 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as PMV Pharmaceuticals
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 30% of workforce | Restructuring planSEC 8-K | “(the “ Company ”) announced a restructuring plan involving the reduction of its workforce by approximately 30% of the Company’s employees.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How PMV Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$113 M · higher than 38% of 726
- Price / book1.1× · lower than 78% of 534
- FCF yield-65.4% · higher than 19% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| PMV Pharmaceuticals, Inc.🇺🇸 | $113 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 9, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at PMV Pharmaceuticals, Inc.? Verify and update this profile — free
Show PMV Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.